Human colorectal tumor tissue-derived ALI organoids were cultured as described previously [10 (
link)]. The medium components were as follows: Advanced Dulbecco’s Modified Eagle’s Medium (DMEM) with 50% Wnt, Noggin and R-Spondin conditioned medium; GlutaMax; B-27 supplement; 100 μg/mL
Primocin (Invitrogen, Carlsbad, CA, USA); 1 mM
N-Acetyl-
l-cysteine; 10 mM
Nicotinamide (Sigma-Aldrich, St. Louis, MO, USA); 50 ng/mL
mouse epidermal growth factor (EGF) (PeproTech, Inc., Rocky Hill, NJ, USA); 500 nM
A83-01 (Adooq Bioscience, Irvine, CA, USA); and 3 μM
SB202190; 10 μM
Y-27632 (Cayman, Ann Arbor, MI, USA). Stem cell-related signal inhibitors were as follows: YO-01027 (Toronto Research Chemicals, Toronto, Canada); DAPT (Adooq Bioscience); WAV939;
Wnt-C59;
AY9944; and
GANT61 (Cayman). Anti-cancer drugs were as follows: 5-FU (WAKO, Tokyo, Japan);
Irinotecan (LC Laboratories, Woburn, MA, USA); and
Oxaliplatin (Adooq Bioscience). Antibody sources were as follows: GLI-1 (Gene Tex, Irvine, CA, USA); CD44 (Bethyl Laboratories, Montgomery, TX, USA);
c-Myc; and
Nanog (Cell Signaling, Beverly, MA, USA). Secondary antibodies were as follows: Horseradish peroxidase (HRP) conjugated anti-rabbit IgG; HRP conjugated anti-goat IgG (Cayman); and
HRP conjugated anti-mouse IgG (Millipore, Temecula, CA, USA).
Usui T., Sakurai M., Umata K., Elbadawy M., Ohama T., Yamawaki H., Hazama S., Takenouchi H., Nakajima M., Tsunedomi R., Suzuki N., Nagano H., Sato K., Kaneda M, & Sasaki K. (2018). Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture. International Journal of Molecular Sciences, 19(4), 1098.